Baird Reiterates Outperform Rating on Acadia Pharmaceuticals (ACAD), SAN711 deal is 'incrementally positive'
Tweet Send to a Friend
Baird analyst Joel Beatty reiterated an Outperform rating and $28.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).The analyst commented: "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
